stockrow
Friday 6 November 2026
Export TKNO’s income statement to Excel — free account
Alpha Teknova, Inc.
TKNO Healthcare Drug Manufacturers Specialty & Generic
Alpha Teknova, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 7.35% from fiscal 2024.
- Revenue
- +21.5%
- EPS
- +25.0%
- Free cash flow
- +40.9%
- Total debt
- +1.48%
Quarter to September 2026, against a year earlier
7.76
0.12
−1.52%
Follow TKNO
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
10.40 | 6.97 | 3.71 | 5.02 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(373.93) | (646.81) | (46.12) | (439.90) | |
P/B ratio |
7.99 | 4.87 | 2.39 | 2.96 | |
Price to Tangible BV |
9.81 | 5.95 | 2.91 | 3.58 | |
EV/Sales |
10.42 | 6.97 | 3.69 | 4.91 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(85.93) | (48.54) | (19.53) | (23.02) | |
EV/FCF |
(74.97) | (41.41) | (17.03) | (20.33) | |
Quick Ratio |
2.51 | 3.32 | 3.40 | 3.44 | |
Current Ratio |
3.56 | 4.49 | 4.59 | 4.58 | |
Net Debt/EBITDA |
0.00 | 3.31 | 1.65 | 2.69 | |
Debt/Assets |
14.01% | 13.79% | 13.35% | 12.67% | |
Debt/Equity |
0.22 | 0.21 | 0.20 | 0.19 | |
Asset Turnover |
0.45 | 0.42 | 0.39 | 0.36 | |
Operating CF/Net income |
0.37 | 0.15 | 0.74 | 0.10 | |
Capex/Depreciation |
0.00 | (0.08) | (0.15) | (0.22) | |
Interest Coverage |
(12.38) | (11.47) | (19.63) | (21.84) | |
Research and Development Expense of Revenue |
4.57% | 4.55% | 5.50% | 5.23% | |
Selling, General and Administrative Expense of Revenue |
56.39% | 56.91% | 64.87% | 70.55% | |
Intangible Assets out of Total Assets |
0.12 | 0.12 | 0.12 | 0.12 | |
Share Based Compensation of Revenue |
4.82% | 5.10% | 6.27% | 7.78% | |
Graham Net Nets |
(0.01) | (0.01) | (0.01) | 0.00 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(3.26%) | (5.46%) | (11.07%) | (8.68%) | |
Free Cash Flow Yield |
(1.34%) | (2.41%) | (5.85%) | (4.82%) | |
Revenue per Share |
0.24 | 0.23 | 0.21 | 0.19 | |
Operating CF per Share |
(0.02) | (0.01) | (0.06) | (0.01) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.03) | (0.01) | (0.07) | (0.02) | |
Cash per Share |
0.31 | 0.33 | 0.33 | 0.40 | |
Shareholders Equity per Share |
1.11 | 1.17 | 1.21 | 1.29 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.11 | 1.17 | 1.21 | 1.29 | |
Free Cash Flow |
(1.40) | (0.60) | (3.58) | (0.81) | |
Working Capital |
22.87 | 23.95 | 24.78 | 26.97 | |
Capital Expenditures |
(0.12) | (0.12) | (0.22) | (0.35) | |
Net Current Asset Value |
(3.10) | (2.45) | (2.06) | (0.30) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.02 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
5.48 | 5.27 | 5.64 | 4.47 | |
Average Payables |
1.45 | 1.32 | 1.59 | 1.10 | |
Average Inventory |
7.20 | 7.26 | 6.72 | 6.93 | |
Average Assets |
101.15 | 103.18 | 106.33 | 111.18 | |
Average Common Equity |
66.22 | 69.33 | 71.76 | 75.58 |
Columns are period end dates · fundamentals updated 5 Nov 2026